Pheochromocytoma is an efficient catecholamine-secreting tumor of the
adrenal gland medulla. Catecholamines include norepinephrine,
epinephrine, and their derivatives. Symptoms of pheochromocytoma
include flank skin, elevated heart rate, elevated blood pressure,
anxiety, sweating, headache, and weight loss. Within normal limits,
norepinephrine and epinephrine hormones are responsible for
regulating the blood pressure and heart rate. Excess production of
catecholamine due to pheochromocytoma is a reason for high blood
pressure with life-threatening and potentially serious difficulties
such as stroke and heart attack. Pheochromocytoma occurs most
frequently in adults aged between 30 and 60 years. Pheochromocytomas
are not life-threatening mostly, but have 10% chances of being
cancerous. High blood pressure is the most significant symptom;
however, excessive sweating, light-headedness, a fast and pounding
pulse when standing, severe headache, rapid breathing, and other
symptoms may also occur.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36065
The pheochromocytoma market can be segmented based on diagnosis,
treatment, and region. Based on diagnosis, the market can be
segmented into laboratory tests, imaging tests, and genetic testing.
Laboratory tests include 24-hour urine test and blood test. These
tests help in measuring the levels of noradrenaline, adrenaline, and
byproducts of these hormones in the patient’s body. Furthermore,
imaging tests include computed tomography (CT) scan, magnetic
resonance imaging (MRI), M-iodobenzylguanidine (MIBG) imaging, and
positron emission tomography (PET). Genetic testing includes profiles
of plasma catecholamine metabolites in patients with hereditary
pheochromocytoma. Based on treatment, the pheochromocytoma market has
been segmented into medications and surgery. Medications include Beta
blockers that decrease the heart rate and reduce the blood pressure
and antihypertensive drugs that lower the blood pressure. Moreover,
surgery includes adrenalectomy, which is surgical removal of one or
both the adrenal glands.
Based on geography, the global pheochromocytoma market can be
segmented into four major regions: North America, Europe, Asia
Pacific, and Rest of World. North America dominates the global
pheochromocytoma market, followed by Europe. Key factors driving the
market in these two regions are growing awareness about malignant
effects of tumor among the people and availability of sophisticated
and technologically advanced treatment options in these regions.
According to Clinical Key, a health care website by Elsevier, Inc.,
the prevalence of tumor is estimated to be around 2 cases per 100,000
individuals in the U.S. every year. Around 5% of adrenal
incidentalomas are pheochromocytomas. Studies have also shown that
about 25% of them are hereditary. Hence, increasing expertise in gene
therapy may also help in curbing the cancer growth.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=36065
Advancements in the diagnosis and treatment of cancer are likely to
add to product offerings in the near future. The prevalence of cancer
is increasing in developing countries. Thus, cost-effective treatment
options are likely to witness high demand in these countries.
According to an article published by Progenics Pharmaceuticals Inc.,
the number of patients in the U.S. is around 4000 to 6000 currently,
with less than 1000 new cases diagnosed in 2016. Additionally,
unhealthy lifestyle habits such as smoking and drinking are
contributing to growth of the pheochromocytoma market in North
America. Asia Pacific is one of the most promising markets for
pheochromocytoma, as the region is developing rapidly. Furthermore,
presence of emerging economies and easy penetration of the market in
developing countries in Asia would drive the pheochromocytoma market
in Asia Pacific in the near future.
Several pharmaceutical companies are currently developing therapeutic
treatments to reduce the malignant effects of the pheochromocytoma.
Some of the top players operating in the global pheochromocytoma
market are Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., Progenics
Pharmaceuticals, Inc., and Valeant Pharmaceuticals International,
Inc.
Report Overview @
https://www.transparencymarketresearch.com/pheochromocytoma-market.html
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment